Gyroscope Therapeutics names Jessica Stitt as CFO
1 March 2021 -

Gene therapy company Gyroscope Therapeutics Limited announced on Mondaythat it has appointed Jessica Stitt as its chief financial officer with immediate effect.

Most recently, Stitt has served as the vice president of Finance and Operations for MyoKardia Inc, a biopharmaceutical company.

Previously, Stitt was employed as the vice president of Finance and Investor Relations for Theravance Biopharma Inc.

Earlier in her career, Stitt has worked at Nektar Therapeutics, Alkermes as well as Blue Cross Blue Shield of Massachusetts.